US OptionsDetailed Quotes
TSVT241220C7500
- 0.05
- 0.000.00%
15min DelayClose Dec 10 16:00 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume1.32K Open Interest7.50Strike Price0.00Turnover248.30%IV91.14%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0809Delta0.0949Gamma79.00Leverage Ratio-0.0120Theta0.0001Rho6.39Eff Leverage0.0010Vega
2seventy bio Stock Discussion
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance
2seventy bio and Bristol Myers Squibbhave decided to discontinue enrollment in the Phase 3 KarMMa-9 studyevaluating Abecma in newly diagnosed multiple myeloma patients. This decision is expected to result in over $80 million in cost savings for 2seventy bio and accelerate their path to breakeven in 2025.
The company reports positive momentum for Abecma, wi...
$Supernus Pharmaceuticals (SUPN.US)$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech (LEGN.US)$ & $Johnson & Johnson (JNJ.US)$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca (AZN.US)$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio (TSVT.US)$ & $Bristol-Myers Squibb (BMY.US)$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals (VNDA.US)$...
WSJ· 2 mins ago
Bristol Myers Squibb and 2seventy bio have won U.S. Food and Drug Administration approval for the earlier use of their Abecma gene therapy in the treatment course for people with the blood cancer multiple myeloma.
The companies on Friday said the FDA approved Abecma for the treatment of adults with relapsed or refractory multiple myeloma after two or more prior lines of therapy, ...
- Company Now Exclusively Focused on Development and Commercialization of Abecma -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 1, 2024-- 2seventy bio, Inc. (Nasdaq: TSVT), announced today the completion of the asset purchase agreement (“APA”) by Regeneron Pharmaceuticals, Inc. Under the terms of the APA, Regeneron has acquired all onc...
No comment yet